|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2008-2-28
|
|
pubmed:abstractText |
P63 belongs to the 'p53 family' whose role in cancer progression has been recently revisited in light of the plethora of splicing variants that are generated. We analyzed the expression of the full-length TAp63 gene and its dominant-negative form deltaNp63 in ovarian cancer biopsies to correlate their expression with clinical outcome.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
501-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17998283-Biopsy,
pubmed-meshheading:17998283-DNA-Binding Proteins,
pubmed-meshheading:17998283-Disease Progression,
pubmed-meshheading:17998283-Female,
pubmed-meshheading:17998283-Humans,
pubmed-meshheading:17998283-Middle Aged,
pubmed-meshheading:17998283-Mutation,
pubmed-meshheading:17998283-Neoplasm Staging,
pubmed-meshheading:17998283-Ovarian Neoplasms,
pubmed-meshheading:17998283-Survival Analysis,
pubmed-meshheading:17998283-Trans-Activators,
pubmed-meshheading:17998283-Transcription Factors,
pubmed-meshheading:17998283-Tumor Markers, Biological,
pubmed-meshheading:17998283-Tumor Suppressor Proteins
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
DeltaNp63 expression is associated with poor survival in ovarian cancer.
|
|
pubmed:affiliation |
Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy. marchini@marionegri.it
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
